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ABSTRACT 
Objective: To determine if (poly)phenols alter cardiovascular risk factors, we assessed the 
potential of a high (poly)phenol beverage drink, rich in hydroxycinnamates and flavonoids, to 
modify vascular function in middle aged, overweight or obese subjects without medical co-
morbidity in a randomized placebo controlled pilot study.  Methods: Randomly assigned active 
250ml beverages containing 361mg of (poly)phenols and 120mg of vitamin C or placebo (no 
polyphenol / vitamin C) were taken twice daily for 4 weeks. Both beverages contained 40 
kcals/250 ml. The primary end-points were pulse wave velocity (PWV) and cutaneous 
microvascular responses to sodium nitroprusside (SNP) and acetyl choline (ACh) laser doppler 
iontophoresis.  A range of established and novel plasma markers were also measured.  Results: 
Twenty subjects received active beverage and 19 placebo; all completed the study.  There was no 
difference in cutaneous vascular response to either SNP or ACh with mean group differences 
(log∆ area under perfusion curve) of 0.30 (-0.65, 1.26) and 0.35 (-0.11, 0.81) respectively.  Nor 
was there evidence of a change in log PWV with a mean group difference of 0.029m/s (-0.042, 
0.10). No significant differences were seen in plasma leptin, apolipoproteins, cystatin C, insulin, 
adiponectin, CRP, ICAM-1, E-Selectin or t-PA, but IL-6 increased in active versus placebo 
recipients (0.32 vs – 0.18 pg/ml; p=0.010). Conculsion: There was no evidence for a short-term 
beneficial effect of (poly)phenol intervention on microcutaneous vascular response or pulse 
wave velocity, and no evidence for a benefit on established or novel risk factors in overweight  
or obese subjects.  Our results do not support a short-term benefit of (poly)phenol 
supplementation on cardiometabolic risk. 
 
Registration: Clinical Trials.gov (NCT00795834) 
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1. Introduction 
 
Epidemiological data support consumption of fruits and vegetables in the reduction of 
cardiovascular risk (1-5) leading to supportive recommendations by the World Health 
Organisation (6), European Society of Cardiology (7) and jointly the American College of 
Cardiology and American Heart Association (8).  Many components may contribute to benefits 
including potassium, non-starch polysaccarides, carotenoids, vitamin C and E and phenolic 
compounds with bioactive phytochemical constituents having a C6-C3-C6 flavonoid structure. 
The potential benefits of dietary poly(phenolics) have in particular, received intense research 
interest. (9) The effects of nutritional intervention on “hard” cardiovascular clinical outcomes 
such as myocardial infarction, time to coronary reperfusion, and death, are difficult to assess in 
prospective clinical studies.  Effects on surrogate risk markers for cardiovascular disease can 
give an early indication of future potential.  In addition to traditional modifiable cardiovascular 
risk markers such as lipid profile, smoking, diabetes and blood pressure, a burgeoning number of 
novel plasma biomarkers (10) are joined by non-invasive measurements of vascular function 
such as pulse wave analysis / velocity and cutaneous microvascular responses measured by laser 
doppler iontophoresis (LDI). 
A combination of (poly)phenols from fruits in a single beverage may provide 
administration and compliance benefits when compared to consuming primary fruit and 
vegetable sources.  This pilot study evaluates the potential for such a beverage to modify a range 
of traditional cardiovascular risk markers along with novel plasma biomarkers and vascular 
function measurements. The primary end-point of the study was to evaluate vascular function 
using pulse wave studies, and LDI after intervention with the study beverage rich in 
4 
 
(poly)phenols compared to a matched drink without polyphenols.  Secondary end-points 
addressed changes in established and range of novel risk factors.  
 
2. Methods  
A randomized, double blind, placebo controlled design was employed with a 1:1 allocation 
of subjects to parallel active and placebo arms. The beverages were manufactured and supplied 
by the Coca-Cola Company. The active drink contained 28% beverage, water and non-nutritive 
sweeteners (sucralose and acesulphame-K). The polyphenolic and hydroxycinnamate content 
was derived from green tea, grape seed, grape pomace, ruby red grape juice, lemon and apple 
extracts. The predominant active constituents in the 250ml beverage portion comprised the green 
tea derived flavan-3-ols (348µmol), mainly epigallocatechin (134µmol) and gallic acid (37µmol); 
5-O-caffeoylquinic acid (33µmol) and dihydrochalcones (59µmol) from apples; citrus flavanones 
(36µmol); a range of flavonols (7µmol) and grape anthocyanins (5.6µmol). The grape seed 
component provided 72mg of procyanidins. The placebo beverage was coloured, flavoured and 
sweentened to be as similar as possible to the active beverage, but rendered (poly)phenol free, 
without beverage or extracts. The colouring and flavouring were felt highly unlikely to confer 
any biological activity. Properties of the active and placebo beverages are shown in Table 1.  
Bioavailability of a range of plasma and urinary metabolites including those related to the flavan-
3-ols, flavanones, dihydrochalcones and 5-O-caffeoylquinic acid, was confirmed in 10 healthy 
volunteers following a diet low in flavonoids for 48 hrs (11).  The blended active beverage 
delivered a similar range of flavonoid and phenolic compounds as if several different plant-
derived fruits and tea were consumed independently. 
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Following local ethics committee approval and advertising in regional newspapers, subjects 
were initially telephone screened and then invited to a formal screening visit at which informed 
consent was obtained. Screening measurements included weight, height and blood pressure and 
12 lead ECG. Biochemistry and haematology profiles were analysed by the routine National 
Health Service laboratory at the Western Infirmary, Glasgow and included urea and electrolytes 
for estimated  glomerular filtration rate (eGFR), liver function tests (LFT), full blood count and 
glycosylated haemoglobin (HbA1C).  Suitable subjects included those over 55 years with a body 
mass index greater than 25 kg/m2.  Exclusion criteria included current and ex-smokers of less 
than 2 years, HbA1C > 5.5%, eGFR<60ml/min/1.73m
2, LFTs ≥ 3 times upper limit of normal, on 
medication for hypertension or BP >160mm Hg systolic, >90mm Hg diastolic, chronic disease 
associated with increased cardiovascular risk (cardiorespiratory, rheumatological, neoplastic), 
vitamin supplementation within the previous 14 days, and on medication likely to influence 
vascular function (eg corticosteroids).  The study entry criteria were designed to include subjects 
with increased cardiovascular risk purely on the basis of their age and being overweight or obese.  
Following enrollment by the study team, subjects were randomized to receive active or placebo 
beverage, consecutively in groups of 10 balanced for gender. Randomization and subject 
assignment was arranged by the University of Glasgow School of Mathematics and Statistics; the 
study team was blinded to the allocation sequence. Previous studies using nutritional 
interventions to modify vascular markers were consulted for power estimations and a target of 40 
completed subjects determined (12-16). There were no changes to the study protocol entry 
criteria or outcome measures following commencement.  
The study was registered with Clinical Trials.gov, identifier NCT00795834.  Guidelines 
issued by the National Patient Safety Agency (Research Ethics Service) were consulted to 
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confirm the status of the intervention as a food grade product.  The principles of Good Clinical 
Practice were applied to all aspects of the study.  Participants received a payment of £100 on 
completion as compensation for time spent on study activity, and transport costs were refunded.    
All measurements were carried out at the British Heart Foundation Glasgow 
Cardiovascular Research Centre at the University of Glasgow.  Subjects were advised to 
continue their normal diet and attend for baseline measurements fasted, in the morning, having 
completed a detailed food diary over the preceding 72 hours. The primary end-points were pulse 
wave velocity (PWV) and cutaneous microvascular responses to sodium nitroprusside (SNP) and 
acetyl choline (ACh) laser doppler iontophoresis. Secondary outcomes included anthropometric 
measurements and a range of established and novel plasma markers. A defined sequence was 
followed: 1. Laser doppler iontophoresis (LDI):  The protocol used for assessment of 
microcutaneous skin response by LDI has been validated (17) and described in detail in clinical 
studies (12, 13). In brief: in a temperature controlled room and with skin temperature 
acclimitisation, cutaneous microvascular responses to topically applied vasoactive acetyl choline 
(ACh) and sodium nitroprusside (SNP) were assessed using a laser Doppler imager (Moor LDI-
2; Moor Instruments, Axminster, UK). Iontophoresis was contained within 2 topically applied 
wells (ACh in the anodal chamber and SNP in the cathode) and a total of 20 scans were 
conducted with incremental current delivery.  Doppler images were then interrogated to calculate 
skin perfusion.  Sigma Chemicals, Poole, UK provided the iontophoresis chemicals which were 
dissolved fresh for daily use in 0.5% NaCl stock solution to a concentration of 1%.  2. 
Anthropometry: Height was measured using a Seca® stadiometer; weight and bioelectrical 
impedance were jointly measured using a Tanita® BC-418MA Body Composition Analyser, and 
waist was determined using a non-stretch tape. 3. Blood Pressure recordings were made using a 
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DinaMap® Pro 200 according to the guidelines of the American Heart Association (18). 4. Pulse 
wave measurements were made using a SphygmorCor® tonometer device and immediate data 
analysis software (AtCor Medical Pty Ltd, West Ryde, NSW, Australia.  Pulse wave analysis at 
the wrist determined aortic augmentation index (AAI), and pulse wave velocity (PWV) was 
measured using carotid and femoral arterial waveforms.  Using the live quality control analysis, a 
minimum of 2 acceptable recordings of AAI and PWV were obtained.  5. Phlebotomy provided 
20ml of venous blood which was immediately centrifuged with plasma aliquots stored at -80æC. 
Batch analysis was conducted at completion of the study by the Department of Biochemistry at 
Glasgow Royal Infirmary.  Enzymatic colorimetric assays were conducted for cholesterol and 
triglyceride; immunoturbidimetric assays were used for ApoB, A1 and sCRP.  Analysis was 
carried out on a Hitachi Modular P analyzer using kits supplied by Roche Diagnosics, Germany.  
VLDL and LDL Cholesterol results were calculated using the Friedwald Equation. IL-6, ICAM, 
sE-Selectin and Adiponectin were analysed using a Multiskan Ascent Plate reader and software 
(Thermolife Sciences, Basingstoke, UK) and kits provided by R&D Systems Europe Ltd, 
Abingdon, UK. Insulin was measured using the Mercodiaultrasenstive insulin ELISA. Leptin 
analysis was performed using an in-house assay; the methodology has been previously published 
(19). t-PA was measured with an ELISA (Biopool AB, Umea, Sweden).  
Following baseline measurements, subjects commenced their allocated study beverage, 
consumed as 250ml doses twice daily for 4 weeks and were advised to continue their normal 
diet. A 2 week supply of beverage was provided at the baseline visit.  Subjects were advised to 
store the beverage in their domestic refrigerator.  Blinded reserve batches were available for 
substitution in the event of damage or loss to the supplements.  The properties of the placebo and 
active beverages are described in Table 1.  The individual (poly)phenolic components in the 
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active beverage were analysed by high performance liquid chromatography-tandem mass 
spectrometry (HPLC-MS2) and the amounts detected were in keeping with the quantities found 
in an earlier batch of the drink used in an acute feeding study (11).  The (poly)phenolic 
compounds were not present in detectable amounts in the placebo drink. 
Subjects attended a mid-point visit, timed to occur 60 minutes after administration of the 
study beverage with subjects otherwise fasted.  The first voided urine in the morning prior to 
administration of the beverage was collected, along with a second urine sample approx. 120 min 
following administration.  Venous blood was drawn at 60 - 90 minutes post administration.  
Plasma and urine samples were frozen at -80 degrees (plasma being archived for possible future 
analysis).  Urine was analysed by HPLC-MS2 as described by Borges et al.  (11) in order to 
assess the presence of flavan-3-ol and dihydrochalcone metabolites derived from intake of the 
(poly)phenol-rich drink. Compliance was also checked by reconciliation of returning packaging; 
tolerance was noted including any adverse events and the second 2 week supply provided.  The 
end-point visit was conducted on completion of the study beverage, with the final dose taken on 
the morning of the visit.  To achieve dietary replication before the 2 main testing points a 
detailed food diary over the preceding 72 hours was again completed, referring to the diary 
completed prior to the baseline visit. Measurements were identical to the baseline visit. The 
study procedure is summarized is Figure 1. 
  Baseline characteristics were compared using 2 sample t-tests or rank-sum for non-
parametric data. LDI perfusion data was extracted from the scan images using Moor software 
and corrected for skin resistance, an important factor in interpretation of LDI data (20, 21).  
Perfusion data for each of the 20 scans per visit in anode and cathode wells were converted to an 
area under curve (AUC) result.  The AUC data were examined for normality and log-
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transformed where appropriate.  Differences in the log transformed AUC data between follow-up 
and baseline visits were calculated for SNP and ACh studies in the active and placebo groups 
and comparisons made using 2 sample t-tests.  For PWV and AAI data, and all secondary 
outcomes, paired differences were calculated - a positive value meaning the measure increased 
over time.  Two-way ANOVA on paired differences was determined with an additive model: 
Gender + Group. If residuals appeared normal, analysis proceeded; otherwise, differences of logs 
were taken. The p-value for Gender effect was noted: if Gender effect not significant, groups 
were compared using 2-sample t test (pooled SD); if Gender effect significant, groups were 
compared adjusting for Gender in ANOVA. Statistical analysis was carried out using Minitab 15 
with the significance level set at p<0.05 and no adjustment for multiple testing. Specific analysis 
of the dietary records was not intended: they were included as an aide memorie to allow 
replication of the diet before the 2 testing points.  
 
3. Results  
Recruitment and study procedures were conducted over a 6 month period from July 2008 to 
January 2009. 95 subjects responded to advertisements and were checked for eligibility by 
telephone resulting in 53 invitations for formal screening and 49 attendances.  Entry criteria 
resulted in 10 exclusions (BMI: 1, Blood Pressure: 2, Medical history/ECG: 2, HbA1c: 5) 
yielding 39 subjects for enrolment. The aim to reach the recruitment target of 40 subjects was 
balanced with time constraints for study completion considering the shelf-life of the investigative 
product. Baseline characteristics were compared for placebo and active groups (Table 2) and 
demonstrated equivalence in the 2 groups.   
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All 39 enrolled subjects completed the study. There were no serious adverse events and 
tolerability was good.   Compliance with study beverage determined by reconciliation of returned 
packaging was excellent (99% in active, 98% in placebo). In addition, HPLC-MS2 analysis 
detected ten flavan-3-ol and three phloretin metabolites, principally glucuronides and sulfates, 
that had previously been shown to be indicative of intake (11), in the urine of 19 of the 20 
participants in the active arm but none of those who consumed the placebo drink. The results in 
Table 3 demonstrate no significant change in the primary end-points of PWV, or microcutaneous 
skin vascular responses measured by LDI in active versus placebo recipients.  There was a trend 
(p=0.078) towards reduction in AAI.  Similarly, no significant differences in adiposity (weight, 
waist or plasma leptin) or blood pressure are noted although systolic blood pressure trended 
(p=0.097) towards reduction in active drink recipients.  
 
Results in Table 4 show no significant changes in any lipid, renal or metabolic parameter.  
However, a significant (p=0.01) increase in plasma IL-6 was noted in active versus placebo 
recipients. None of the outcomes were altered by repeat analysis excluding data from two 
subjects with likely acute inflammation indicated by elevations in CRP beyond 20mg/l at any 
measurement point during the study.   
 
4. Discussion 
The results of this study did not demonstrate evidence for improvement in microvascular 
function measured by LDI, or in vascular stiffness measured by PWV following 4 weeks 
supplementation with a (poly)phenol-rich fruit and tea-derived beverage in overweight or obese 
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subjects otherwise free from medical comorbidity and possibly considered “metabolically 
healthy obese”, although, as discussed below many were at medium cardiovascular risk by 
modern standards.  Plasma markers of adiposity, lipid profiles, renal and metabolic markers and 
markers of inflammation and endothelial activation did not demonstrate any significant change 
following ingestion of the active supplement.  The exception to this was IL-6 which exhibited a 
statistically significant increase in subjects receiving the active beverage.  IL-6 increases are 
thought to reflect a heightened inflammatory state.  This result was rather unexpected and is not 
easily explained, unless as a Type I statistical error, or represents a regression to the mean. 
Nevertheless, it is important to note that IL-6 signaling is potentially causally linked to 
cardiovascular risk (22); the intriguing possibility that an intervention rich in polyphenols might 
exert a pro-oxidant effect is worthy of examination in future relevant trials.  
The number of subjects was similar to those in other studies of this type, but inevitably the 
power constraints, in particular the between-subject variability, raise the possibility of a type II 
statistical error.  However other factors may explain the results. Cardiovascular (CV) risk 
assessment at baseline using the Joint British Society risk calculators suggested that the majority 
of subjects were at medium risk with six (15%) having a CVD risk above 20% risk threshold.  
Nevertheless, all were overweight and the majority were in the obese category; obesity is a 
strong risk factor for diabetes and other cardiometabolic outcomes and known to lessen life 
expectancy (23). Other researchers using subjects at greater CV risk have found improvements in 
brachial artery flow mediated dilatation (FMD) measurements following isoflavone 
supplementation for 12 weeks in patients with prior ischaemic stroke (24) and similar findings 
have been reported with black tea (25) and purple grape juice (26) in subjects with 
angiographically proven coronary artery disease, though the latter was not a randomized trial. 
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Green tea extracts in Japanese subjects with visceral obesity led to reductions in systolic blood 
pressure however the CV risk status of the included subjects is not clear (27). Conversely, 
increases in systolic blood pressure were seen with a combination of vitamin c and grape-seed 
polyphenols in a study of treated hypertensives (28).  Thus, in totality, including the results from 
the present study, one cannot infer a consistent effect of short term supplements on 
cardiovascular risk surrogates in properly conducted randomized trials of which there are only 
but a few such high quality studies.      
Alcohol ingestion was not specifically limited in study subjects: intake was minimal in most 
subjects however a small number recorded significant consumption in their food records.  
Studies have suggested a potentially protective effect of alcohol on vascular function (29) but it 
is more likely that this is a U-shaped relationship with detrimental effects at excessive levels 
(30). Subjects did attend visits fasted, including abstaining from alcohol from the preceding 
night, however longer term effects of alcohol on vascular reactivity would not be mitigated by 
this.  Another confounding factor relates to the usual diet of subjects during the study phase.  
Ideally, to investigate the effect of a (poly)phenol-rich beverage, all other dietary (poly)phenols 
would be eliminated.  Experience in the preliminary feeding study (11) highlighted how difficult 
a (poly)phenol-free diet is to adhere to rendering this impracticable in a short to medium term 
nutritional study.  Diet records provided some insight but were primarily in place to ensure 
replication of diet in the days before visits – the only practical way to exert some control over 
dietary confounding. We did not intend to perform a detailed analysis of the diet records 
however a provisional review of the quality of the dietary recordings suggested that they were 
unlikely to provide meaningful results, or alter interpretation of the outcome. We elected not to 
ask subjects to keep a dietary record for the entire 4 week study period as it would have been 
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similarly unlikely to have contributed useful data and would have been particularly onerous to 
complete, threatening study compliance. Dietary records are notoriously inaccurate particularly 
in overweight and obese subjects who usually under-report intake. The absence of any weight 
change in subjects during the study period strongly suggests that there were no significant dietary 
fluctuations.  Variations in diet and the inability to accurately control or record this is a 
significant confounding factor in studies of this type but there are few practical alternatives.  An 
alternative approach, adopted by Plotnick et al assessed the ability of fruit and vegetable 
concentrates taken over 4 weeks, to mitigate the acute effects of a high fat meal on vascular 
reactivity.  Those supplemented with the phytochemical concentrates exhibited blunting of the 
effect of high fat ingestion on brachial artery FMD measurement (31).   
The administration of multiple fruit constituents in a single beverage offers compliance 
benefits and is an attractive means to assess the potential of phytochemicals to modify vascular 
risk markers. Our preliminary bioavailability study confirmed excellent (poly)phenol 
bioavailablity and tolerance. Recovery of urinary metabolites and plasma pharmacokinetics of 
flavan-3-ol, flavanone and dihydrochalcone phase II metabolites absorbed in the proximal and 
distal gastrointestinal tract were broadly comparable to other feeding studies with green tea, 
coffee, apple cider, orange juice and green tea (11).  The active beverage delivered a daily 
polyphenol dose of 722mg; comparable to that reported in observational studies examining the 
effect of a Mediterranean Diet high in (poly)phenol foods on cardiovascular events (32). 
Much of the research in this field involves small studies, relatively few of which are placebo 
controlled or indeed randomized or blinded.  All of these interventional studies, including this 
research, depend on surrogate markers such as LDI, Pulse Wave studies, FMD or the plethora of 
proposed plasma biomarkers.  These are convenient to measure at time-points before and after an 
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intervention but it should be stressed that they are not a replacement for true cardiovascular 
outcomes such as myocardial infarction and stroke.  This pilot study has shown no convincing 
evidence for beneficial effects on cardiovascular risk markers and joins a very limited number of 
mainly negative studies in similar populations (33).  That noted, pilot evidence for an effect on a 
urinary proteomic-derived coronary artery disease biomarker was noted after 2 weeks with the 
active beverage in this study (34), similar to another study in healthy volunteers taking olive oil 
for an equivalent duration(35), though the relevance of these changes for future risk is not yet 
established. Larger studies with longer follow up, possibly over several years, and including, 
where possible, cardiovascular risk markers such as carotid intima-media thickness 
measurements are necessary to better assess the potential for phytochemicals to modify vascular 
risk. We recognize that effects of diet on health may develop over longer time-spans, although of 
interest, some lifestyle interventions (e.g. increased activity) can show rapid benefit.  Ingestion 
of flavan-3-ols such as cocoa has been associated with lower blood pressures in an observational 
study of elderly men (36) and improved coronary vasodilatation after acute consumption in heart 
transplant recipients (37), suggesting rapid changes in functional measures with flavan-3-ols. It 
remains possible however that, despite suggestive in vitro evidence and supportive prior trials, 
isolated (poly)phenols may not exert beneficial effects on CV risk.  Positive reporting bias is a 
particular problem in interventional studies, particular in the field of nutritional supplementation, 
and as such our results are a timely reminder for the need for more detailed and robust trials in 
this area in the future.    
For the purposes of this short-term study examining the effects of a nutritional interventional 
in isolation, it was necessary for subjects to maintain their usual diet and no significant weight 
loss was desired or observed during the study. It is highly possible that beneficial effects of a 
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nutritional intervention will be attenuated or negligible without concomitantly addressing activity 
levels and weight loss.  In other words, our results could be interpreted as further highlighting the 
importance of the need to change usual lifestyle risk factors (diet and activity levels) to alter risk, 
rather than assuming supplements will lessen risk for which robust evidence is largely missing.    
 
5. Summary 
In summary, in this randomized trial, we could not demonstrate any evidence for a short-
term beneficial effect of a (poly)phenol-enriched drink on microcutaneous vascular response or 
pulse wave velocity, and no clear evidence for a benefit on established or novel plasma-based 
risk factors.  
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Highlights 
 
What Is New?  
• Whilst there are supportive observational data, randomised placebo-controlled trials on polyphenol are sparse but urgently needed 
• Our study which meets CONSORT criteria is one of the best in this area using a range of vascular and established and novel risk factors   
 
What Is Relevant? 
• (Poly)phenols are suggested to protect against cardiovascular risk but data quality are weak  
 
Summary of the conclusions of the study 
• We did not demonstrate any evidence for a short-term beneficial effect of a 
(poly)phenol-enriched beverage on a range of established or novel cardiovascular risk factors in predominantly obese subjects  
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Table 1: Key properties of Investigational Beverages 
 Active Placebo 
 
Volume (single unit) 250ml 250ml 
 
Total (poly)phenol content (mg) 361 Negligible 
Vitamin C content (mg) 120 0.00 
Caloric value (Kcal/250ml) 40.0 40.0 
 
Vitamin E, carotenoids, cagnesium, 
potassium, sodium 
Negligible 
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Table 2: Baseline Characteristics: 
Characteristic Active Group n=20 
Mean; SD 
Placebo Group n=19 
Mean; SD 
Demographics / non-invasive measures   
Sex (males) 
 
 
10 10 
Age, Years  
 
60.30; 4.60 62.21; 4.26 
BMI  
 
33.08 6.68 31.49; 4.38 
Waist cm  
 
105.66;17.76 105.26; 13.69 
%FAT  
 
37.2 34.8 
Family History Diabetes Mellitus* (y) 
 
 
3 
 
2 
 
Family History CVD** (y) 
 
 
11 
 
8 
 
Smoking Pack Years, Median (IQR) 
 
4.81(18.38) 0.00 (6.00) 
Alcohol Units / Week  
 
11.35; 10.14 11.11; 14.37 
Systolic Blood Pressure, mmHg  
 
135.15; 14.56 136.68; 14.36 
Diastolic Blood Pressure, mmHg  
 
73.85; 8.70 79.11; 7.46 
Ethnic Group: Caucasian  20 18 
Blood results  
HBA1C % 
 
5.43; 0.24 5.42; 0.21 
Leptin, ng/ml  22.04; 13.02 20.24; 15.59 
Cholesterol, mmol/l 5.50; 0.97 5.60; 0.87 
Trigs, mmol/l 1.26; 0.54 1.40; 0.62 
HDL-C, mmol/l 1.34; 0.36 1.20; 0.25 
Apo AI, g/l  148.7; 27.0 140.2; 19.9 
Apo B, g/l 104.0; 17.2 110.4; 20.6 
Cystatin C, mg/l† 0.965; 1.13   0.960; 1.19 
Fast. Glucose, mmol/l 5.32; 0.49  5.09; 0.24 
Adiponect, ng/ml† 6701; 1.79 6836; 1.84 
Insulin, pmol/l† 6.55; 1.55 5.70; 1.86 
CRP, mg/l† 2.56; 2.03 2.20; 2.46 
IL-6, pg/ml† 1.35; 1.92 2.03; 1.90 
ICAM-1, ng/ml† 
 
 
 
 
 
 
223; 1.19 213; 1.28 
E-Selectin, ng/ml† 
 
 
33.8; 1.82 32.8; 1.55 
t-PA, IU/ml 9.21; 2.25 7.88; 2.26 
 
Vascular function measures 
Log (∆ACh AUC)§ 
 
6.43; 1.27  7.04; 1.00  
Log (∆SNP AUC)§ 6.22; 1.47  6.72; 1.03 
Log (PWV) meters/sec 2.12; 0.16  2.20; 0.20  
AAI  0.35; 0.094  0.36; 0.091 
Log (∆ACh AUC)§ 
 
6.43; 1.27  7.04; 1.00  
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All results as Mean; SD unless otherwise stated; †Geometric Mean; Geometric SD. 
* Type 1 or 2 DM in a first degree relative; **HT, IHD, PVD or Cerebrovascular disease in a first degree 
relative; §Results corrected for skin resistance.  CVD – cardiovascular disease; IQR – interquartile range; 
HBA1C – glycosylated haemoglobin; HDL – high density lipoprotein; Apo A1- apolipoprotein A1; Apo 
B – apolipoprotein B; CRP – C reactive protein; IL-6 – interleukin-6; ICAM-1 –intracellular adhesion 
molecule 1; t-PA – tissue plasminogen activator;  ACh – acetylcholine; SNP – sodium nitroprusside; 
AUC – area under curve; PWV – pulse wave velocity; AAI – aortic augmentation index  
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Table 3: Primary End Points: measures of Vascular Function / blood flow 
 Active Group 
Mean diff (SD) 
N=20 
Placebo Group 
Mean diff (SD) 
N=19 
Group difference: 
Mean (95% CI) 
 
Primary end-points 
log(∆ACh AUC)* 0.00 (1.8) -0.30 (0.89) 0.30 (-0.65, 1.26)  
log(∆SNP AUC)* 0.098 (0.77) -0.25 (0.61) 0.35 (-0.11, 0.81) 
Log(PWV)meters/sec 0.013 (0.12) -0.016 (0.10) 0.029 (-0.042, 0.10) 
Other vascular measure  
AAI -0.022 (0.064) 0.011 (0.048) -0.033 (-0.070, 0.004) 
ACh – acetylcholine; SNP – sodium nitroprusside; AUC – area under curve; PWV – pulse wave velocity; AAI – 
aortic augmentation index  
*Results corrected for skin resistance.   
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Table 4: Secondary End-Points 
 Active Group 
Mean diff (SD) 
N=20 
Placebo Group 
Mean diff (SD) 
N=19 
Group difference: 
Mean (95% CI) 
 
Adiposity and blood pressure 
Weight, kg 0.40 (1.1) 0.63 (0.8) -0.22 (-0.86, 0.42) 
Waist, cm 0.01 (1.3) -0.53 (1.5) 0.55 (-0.37, 1.47) 
Leptin, ng/ml 0.86 (3.7) 0.42 (4.2) 0.44 (-2.13, 3.02) 
%Body Fat 0.36 (1.8) -0.68 (2.9) 1.05 (-0.55, 2.65) 
Systolic BP, mmHg -3.4 (13.3) 3.1 (10.2) -6.5 (-14.2, 1.2) 
Diastolic BP, mmHg -1.6 (6.5) -2.4 (4.5) 0.7 (-2.9, 4.4) 
Lipids and apolipoproteins 
Cholesterol, mmol/l -0.044 (0.43) 0.044 (0.57) -0.088 (-0.414, 0.239) 
Trigs, mmol/l 0.003 (0.32) 0.099 (0.33) -0.096 (-0.306, 0.114) 
HDL-C, mmol/l -0.017 (0.087) 0.034 (0.107) -0.050 (-0.113, 0.013) 
Apo AI, g/l  -1.05 (8.4) 3.20 (11.6) -4.28 (-10.82, 2.26) 
Apo B, g/l 0.34 (8.4) 0.40 (11.9) -0.02 (-6.67, 6.64) 
 
Renal and metabolic markers 
log(Cystatin C, mg/l) 0.018 (0.074) 0.009 (0.053) 0.009 (-0.033, 0.051) 
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Fast. Glucose, mmol/l -0.015 (0.43) 0.021 (0.40) -0.036 (-0.308, 0.236) 
log(Adiponect, ng/ml) -0.007 (0.17) 0.063 (0.18) -0.070 (-0.183, 0.043) 
log(Insulin, pmol/l) 0.002 (0.37) -0.015 (0.46) 0.024 (-0.230, 0.279) 
 
Inflammatory and endothelial activation markers 
log(CRP, mg/l) 0.31 (1.01) -0.13 (0.68) 0.44 (-0.12, 1.00) 
log(IL-6, pg/ml) 0.32 (0.63) -0.18 (0.48) 0.49 (0.13, 0.86)* 
log(ICAM-1, ng/ml) 0.040 (0.090) 0.035 (0.090) 0.005 (-0.054, 0.063) 
log(E-Selectin, ng/ml) -0.006 (0.20) -0.029 (0.25)  0.028 (-0.109, 0.164) 
t-PA, IU/ml 0.36 (2.0) 0.34 (1.4) 0.02 (-1.10, 1.14) 
*p<0.05  
Apo A1- apolipoprotein A1; Apo B – apolipoprotein B; CRP – C reactive protein; IL-6 – interleukin-6; ICAM-1 –
intracellular adhesion molecule 1; t-PA – tissue plasminogen activator   
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Figure 1: 
Study Flow 
Telephone Eligibility Check for 95 subjects 
Screening slots booked for 53 subjects 
(gender balanced; 1:1 male:female) 
Visit 2: Baseline Visit 
 
Bloods, BP, waist + weight 
 
Laser Doppler Iontophoresis and 
Pulse Wave Velocity 
Randomization and Stratification 
by Sex: 39 Subjects 
Visit 4: Final Visit 
Bloods, BP, waist + weight 
Laser Doppler Iontophoresis and 
Pulse Wave Velocity 
72 Hour Diet Record 
Fast from 10pm before visit 2 
72 Hour Diet Replicate + Record + 
Fast from 10pm before visit 4 
 
19 Subjects 
PLACEBO Beverage 
250ml BD for 2 weeks 
20 Subjects 
ACTIVE Beverage 
250ml BD for 2 weeks 
Inclusion / Exclusion Criteria 
  
49 Subjects 
Visit 1: Screening and Consent 
Enrolment: 
39 subjects Exclusion 
Ongoing adjustment 
of screening slots 
based on gender 
ratio of enrolled 
subjects 
Forward abnormal 
results to GP 
Visit 3: Compliance 
check + re-supply 
ACTIVE Beverage 
250ml BD for 2 weeks 
Visit 3: Compliance 
check + re-supply 
 
PLACEBO Beverage 
250ml BD for 2 weeks 
